Poolbeg Pharma (STU:7JN) Accounts Receivable : €0.01 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Poolbeg Pharma Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Poolbeg Pharma's accounts receivables for the quarter that ended in Jun. 2024 was €0.01 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Poolbeg Pharma's Net-Net Working Capital per share for the quarter that ended in Jun. 2024 was €0.02.

Poolbeg Pharma Accounts Receivable Historical Data

The historical data trend for Poolbeg Pharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma Accounts Receivable Chart

Poolbeg Pharma Annual Data

Trend

Dec21

Dec22

Dec23

Accounts Receivable

0.01

Poolbeg Pharma Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Accounts Receivable	Get a 7-Day Free Trial			-	-	0.01	-	0.01

Poolbeg Pharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Poolbeg Pharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Poolbeg Pharma's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.013	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Poolbeg Pharma's accounts receivable are only considered to be worth 75% of book value:

Poolbeg Pharma's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(11.891	+	0.75 * 0.013	+	0.5 * 0	-	0.663
-	0	-	0)	/	500.000
=	0.02

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Poolbeg Pharma Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Poolbeg Pharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Poolbeg Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (STU:7JN) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

POLB:UK 7JN:Germany

Address

42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX

Website

https://www.poolbegpharma.com

Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.

Poolbeg Pharma Headlines

No Headlines